Atorvastatin

證據等級: L5

預測適應症: 6 個

Atorvastatin: From Dyslipidemia to Familial Hypercholesterolemia

One-Sentence Summary

Atorvastatin is a second-generation synthetic statin and HMG-CoA reductase inhibitor, widely established for the treatment of dyslipidemia and prevention of cardiovascular disease. The TxGNN model predicts it may be effective for Familial Hypercholesterolemia (FH), a monogenic disorder of LDL metabolism causing severely elevated LDL-C from birth, with 35 clinical trials and 19 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not retrievable from Canada database (0 DINs on record)
Predicted New Indication	Familial Hypercholesterolemia
TxGNN Prediction Score	99.42%
Evidence Level	L1
Canada Market Status	Not Marketed (0 DINs on record)
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the connected database. Based on well-established pharmacological knowledge, atorvastatin is a potent inhibitor of HMG-CoA reductase — the rate-limiting enzyme in hepatic cholesterol biosynthesis. By depleting intracellular cholesterol, atorvastatin triggers compensatory upregulation of LDL receptor (LDLR) expression on hepatocyte surfaces, dramatically increasing the clearance of circulating LDL-C particles from the bloodstream. Its long half-life (~20–30 hours) and active metabolites provide sustained HMG-CoA reductase inhibition throughout the day.

Familial hypercholesterolemia is caused by loss-of-function mutations in the LDLR gene, apolipoprotein B (APOB), or gain-of-function mutations in PCSK9, all of which impair LDL-C clearance and result in lifelong LDL-C elevation averaging 2–3 times normal. Although atorvastatin cannot repair the underlying genetic lesion, it addresses the shared downstream consequence: excessive circulating LDL-C. By maximally upregulating residual LDLR activity (particularly relevant in heterozygous FH where one functional LDLR allele remains) and suppressing de novo cholesterol synthesis, atorvastatin partially compensates for the receptor deficiency. In homozygous FH, even partial LDLR upregulation provides meaningful, though incomplete, LDL-C reduction.

The mechanistic connection is therefore direct, and the clinical evidence is exceptionally well-developed: statins, particularly high-intensity agents such as atorvastatin, are the first-line pharmacological therapy in every major international FH guideline, including those from the European Atherosclerosis Society (EAS), the American College of Cardiology/American Heart Association (ACC/AHA), and the American Association of Clinical Endocrinologists (AACE). The high TxGNN prediction score (99.42%) faithfully reflects this established mechanistic and clinical reality.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01507831	Phase 3	Completed	2,341	Large-scale RCT assessing long-term safety and tolerability of alirocumab added to atorvastatin-based background therapy in high-CV-risk FH patients; the largest trial in this dataset and highest evidence weight
NCT01623115	Phase 3	Completed	486	Double-blind, placebo-controlled RCT evaluating alirocumab vs. placebo on LDL-C reduction after 24 weeks in heterozygous FH patients on stable atorvastatin background therapy
NCT01730040	Phase 3	Completed	355	Head-to-head RCT comparing alirocumab add-on vs. atorvastatin dose increase vs. rosuvastatin switch in patients with heFH or high CV risk; directly establishes atorvastatin as the clinical benchmark comparator
NCT01709500	Phase 3	Completed	249	Double-blind, placebo-controlled, parallel-group study of alirocumab in heterozygous FH patients not adequately controlled on lipid-modifying therapy (primarily atorvastatin-based)
NCT03867318	Phase 3	Completed	621	Efficacy and safety of ezetimibe 10 mg added to atorvastatin in heFH or CHD patients with primary hypercholesterolemia not controlled on atorvastatin 10 mg monotherapy
NCT00827606	Phase 3	Completed	272	Three-year prospective study characterizing growth, development, and cholesterol-lowering efficacy of atorvastatin in pediatric patients (age 6–17) with heterozygous FH
NCT03885921	Phase 3	Completed	44	24-month open-label extension study of ezetimibe co-administered with atorvastatin or simvastatin in homozygous FH; provides long-term tolerability data
NCT01107743	N/A	Completed	1,291	Post-marketing drug use investigation of amlodipine/atorvastatin (Caduet) in daily medical practice; provides real-world safety and efficacy data
NCT00145431	Phase 3	Terminated	41	Crossover study of torcetrapib/atorvastatin combination in familial dysbetalipoproteinemia; terminated early due to torcetrapib cardiovascular safety signals; atorvastatin arm data partially informative
NCT00739999	Phase 1	Completed	39	Pharmacokinetics, pharmacodynamics, safety, and tolerability of atorvastatin in children and adolescents with heterozygous FH; supports dosing decisions in pediatric populations

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9793596	1998	RCT	Ann Pharmacother	Foundational review of atorvastatin efficacy and safety in primary hypercholesterolemia and mixed dyslipidemias; establishes clinical profile
27417002	2016	Meta-analysis/Cohort	J Am Coll Cardiol	Statin therapy significantly reduces coronary artery disease events and all-cause mortality in heterozygous FH; provides direct outcome evidence
39751968	2025	Review	Curr Atherosclerosis Rep	Comprehensive review of novel pharmacological therapies (including statins as backbone) for homozygous FH; contextualizes atorvastatin within the evolving treatment landscape
28437620	2017	Clinical Guideline	Endocr Pract	AACE/ACE clinical practice guidelines for dyslipidemia management and cardiovascular disease prevention; statins designated first-line agents for FH
26988948	2016	Practice Guidelines	J Am Coll Cardiol	Guidance on improving monitoring and care of FH patients; high-intensity statins including atorvastatin recommended as cornerstone therapy
35361995	2022	Genetic Epidemiology	Pharmacogenomics J	NGS strategy combining FH genetic diagnosis with statin pharmacogenomics; supports individualized atorvastatin dosing in FH based on genotype
22957727	2013	Clinical Study	Echocardiography	Atorvastatin treatment improves myocardial and peripheral blood flow in FH patients without overt coronary atherosclerosis; demonstrates pleiotropic vascular benefits
11383320	2001	Clinical Study	Nutr Metab Cardiovasc Dis	Head-to-head comparison of atorvastatin vs. simvastatin in achieving NCEP LDL-C targets in heterozygous FH; atorvastatin demonstrated superior goal attainment
27678432	2016	Clinical Study	J Clin Lipidol	Three-year assessment of atorvastatin in children/adolescents (age 6–17) with heFH, including growth and safety monitoring; supports long-term pediatric use
10582478	1999	Review	Rev Med Bruxelles	Detailed review of atorvastatin mechanism of action: HMG-CoA reductase inhibition, prolonged half-life of active metabolites, and upregulation of hepatic LDL receptors

Canada Market Information

No drug identification numbers (DINs) for atorvastatin were returned by the Canada regulatory database at the time of this analysis (data cutoff: 2026-04-05). A table cannot be generated from empty records.

Data Note: This finding likely reflects an incomplete data ingestion rather than true absence from the Canadian market. Health Canada’s Drug Product Database should be queried directly to confirm current approval status, active DINs, and approved indications before any regulatory conclusion is drawn.

Safety Considerations

Please refer to the package insert for safety information.

Data Gaps Requiring Remediation:

DG001 (Blocking): Health Canada product monograph warnings and contraindications have not been retrieved. Download and parse the PDF monograph from Health Canada’s website before safety screening proceeds.

DG002 (High): DrugBank MOA and toxicity data have not been retrieved. Query the DrugBank API using DB01076 to obtain pharmacological action, contraindications, and adverse effect profile.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence base for atorvastatin in familial hypercholesterolemia is among the strongest in this drug repurposing analysis, with multiple completed Phase 3 RCTs (including a landmark trial of n=2,341), consistent support across international clinical guidelines, and a directly applicable, well-characterized mechanism of action. An L1 evidence level and 99.42% TxGNN prediction score jointly support advancement.

To proceed, the following is needed:

Regulatory verification: Confirm current Canada DIN status through Health Canada’s Drug Product Database; retrieve all active approvals and their associated indications
Safety data remediation (Blocking — DG001): Download and parse the Health Canada product monograph PDF to extract warnings, contraindications, and precautions before S1 safety screening
MOA data remediation (High — DG002): Query DrugBank API (DB01076) to populate mechanism of action, pharmacological class, and toxicity fields
Drug-drug interaction review: Assess interactions with commonly co-prescribed medications in FH patients (fibrates, cyclosporine, macrolide antibiotics, azole antifungals, PCSK9 inhibitors) given atorvastatin’s CYP3A4 metabolism
Safety monitoring plan: Define monitoring parameters including ALT/AST (hepatotoxicity), creatine kinase (CK) for myopathy/rhabdomyolysis risk, renal function, and blood glucose (risk of new-onset diabetes)
Pediatric dosing guidance: Incorporate data from NCT00827606 and NCT00739999 for patients under 18 years with heFH
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.